Literature DB >> 20722613

Bisphosphonates and bone diseases: past, present and future.

Dominique Heymann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20722613      PMCID： PMC3390739          DOI： 10.2174/138161210793563572

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN： 1381-6128            Impact factor:   3.116


× No keyword cloud information.
  11 in total

Review 1.  Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.

Authors:  J E Dunford
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 2.  Therapeutic approach of primary bone tumours by bisphosphonates.

Authors:  G Moriceau; B Ory; B Gobin; F Verrecchia; F Gouin; F Blanchard; F Redini; D Heymann
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 3.  Prevention and treatment of bone metastases.

Authors:  E J Woodward; R E Coleman
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 4.  A comparison between bisphosphonates and other treatments for osteoporosis.

Authors:  B Le Goff; P Guillot; J Glémarec; J M Berthelot; Y Maugars
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 5.  Bisphosphonate therapy in the treatment of multiple myeloma.

Authors:  M A Lawson; J Ashcroft; P I Croucher
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 6.  Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages.

Authors:  A J Roelofs; K Thompson; F H Ebetino; M J Rogers; F P Coxon
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 7.  Combined therapies of bone disease with bisphosphonates.

Authors:  S P Syddall; P D Ottewell; I Holen
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 8.  Alternative use of bisphosphonate therapy for rheumatic disease.

Authors:  B Le Goff; J-M Berthelot; Y Maugars; E Romas
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 9.  Targeted therapy options for treatment of bone metastases; beyond bisphosphonates.

Authors:  J T Buijs; C C H J Kuijpers; G van der Pluijm
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 10.  Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases.

Authors:  M D Francis; D J Valent
Journal:  J Musculoskelet Neuronal Interact       Date:  2007 Jan-Mar       Impact factor: 2.041
View more
  3 in total

Review 1.  Inflammation, fracture and bone repair.

Authors:  Florence Loi; Luis A Córdova; Jukka Pajarinen; Tzu-hua Lin; Zhenyu Yao; Stuart B Goodman
Journal:  Bone       Date:  2016-03-02       Impact factor: 4.398

Review 2.  Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences.

Authors:  Dominique Heymann
Journal:  J Bone Oncol       Date:  2012-04-26       Impact factor: 4.072

Review 3.  Bisphosphonate-related osteonecrosis of the jaw: a mechanobiology perspective.

Authors:  Estee L George; Yi-Ling Lin; Marnie M Saunders
Journal:  Bone Rep       Date:  2018-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.